Asset Management Industry | Financial Services Sector | Mr. Hansjoerg Plaggemars Dipl.-Kfm., M.B.A. CEO | XETRA Exchange | DE000A3H3L44 ISIN |
DE Country | 3 Employees | - Last Dividend | 1 Mar 2021 Last Split | - IPO Date |
2invest AG is an investment firm with a strategic focus on the biotechnology, life science, and IT sectors, catering to companies primarily located in Germany and extending its interests internationally. Initially known as 4basebio AG, the company underwent a rebranding in January 2021 and is now operating under the name 2invest AG. The firm’s core activities include acquiring, holding, managing, and selling investments. Based in the city of Heidelberg, Germany, 2invest AG positions itself as a key player in promoting and supporting the growth of innovative enterprises in highly dynamic and research-intensive industries.
2invest AG engages in the acquisition of significant stakes in companies and partnerships, especially those within its strategic interest areas of biotechnology, life sciences, and information technology. The company selects entities with potential for high growth and innovation, aiming to be part of their development journey from relatively early stages.
Upon acquisition, 2invest AG takes an active role in managing its portfolio companies. This involves not just overseeing the financial investment, but also providing strategic guidance to ensure these companies can leverage 2invest AG’s expertise to achieve sustainable growth. This may include advising on market expansion, operational efficiency, and technological advancements.
The final aspect of 2invest AG’s business model focuses on the selling or divestiture of its holdings in portfolio companies at an appropriate time, aiming to realize significant capital gains. The strategy involves identifying the optimal timing for exit based on market conditions, maturity of the investment, and achievement of mutual growth objectives, thus ensuring a profitable return on investment.